SEARCH

SEARCH BY CITATION

References

  • 1
    Weber J, McCreaner A, Berrie E, Wadsworth J, Jeffries DJ, Pinching AJ, Harris JR: Factors affecting seropositivity to human T cell lymphotropic virus type III (HTLV-III) or lymphadenopathy associated virus (LAV) and progression of disease in sexual partners of patients with AIDS. Genitourin Med 1986; 62:177180.
  • 2
    Piot P, Laga M: Genital ulcers, other sexually transmitted diseases, and the sexual transmission of HIV. Br Med J 1989; 298:623624.
  • 3
    Fleming D, Wasserheit JN: From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect 1999; 75:317.
  • 4
    Røttingen J, Cameron DW, Garnett GP: A systematic review of the epidemiologic interactions between classic sexually transmitted diseases and HIV: how much really is known? Sex Transm Dis 2001; 28:579597.
  • 5
    Sexton J, Garnett G, Røttingen JA: Metaanalysis and metaregression in interpreting study variability in the impact of sexually transmitted diseases on susceptibility to HIV infection. Sex Transm Dis 2005; 32:351357.
  • 6
    Cameron DW, Simonsen JN, D’Costa LJ, Ronald AR, Maitha GM, Gakinya MN, Cheang M, Ndinya-Achola JO, Piot P, Brunham RC: Female to male transmission of human immunodeficiency virus type 1: risk factors for seroconversion in men. Lancet 1989; 2:403407.
  • 7
    Laga M, Manoka A, Kivuvu M, Malele B, Tuliza M, Nzila N, Goeman J, Behets F, Batter V, Alary M: Non-ulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: results from a cohort study. AIDS 1993; 7:95102.
  • 8
    Wang C, McClelland RS, Reilly M, Overbaugh J, Emery SR, Mandaliya K, Chohan B, Ndinya-Achola J, Bwayo J, Kreiss JK: The effect of treatment of vaginal infections on shedding of human immunodeficiency virus type 1. J Infect Dis 2001; 183:10171022.
  • 9
    Kissinger P, Amedee A, Clark RA, Dumestre J, Theall KP, Myers L, Hagensee ME, Farley TA, Martin DH: Trichomonas vaginalis treatment reduces vaginal HIV-1 shedding. Sex Transm Dis 2009; 36:1116.
  • 10
    Johnson L, Lewis DA: The effect of genital tract infections on HIV-1 shedding in the genital tract: a systematic review and meta-analysis. Sex Transm Dis 2008; 35:946959.
  • 11
    Ghys P, Fransen K, Diallo MO, Ettiègne-Traoré V, Coulibaly IM, Yeboué KM, Kalish ML, Maurice C, Whitaker JP, Greenberg AE, Laga M: The associations between cervicovaginal HIV shedding, sexually transmitted diseases and immunosuppression in female sex workers in Abidjan, Côte d’Ivoire. AIDS 1997; 11:F85F93.
  • 12
    Cu-Uvin S, Hogan JW, Caliendo AM, Harwell J, Mayer KH, Carpenter CC: HIV Epidemiology Research Study. Association between bacterial vaginosis and expression of human immunodeficiency virus type 1 RNA in the female genital tract.1. Clin Infect Dis 2001; 33:894896.
  • 13
    LeGoff J, Weiss HA, Gresenguet G, Nzambi K, Frost E, Hayes RJ, Mabey DC, Malkin JE, Mayaud P, Belec L: Cervicovaginal HIV-1 and herpes simplex virus type 2 shedding during genital ulcer disease episodes. AIDS 2007; 21:15691578.
  • 14
    Anderson B, Cu-Uvin S: Determinants of HIV Shedding in the Lower Genital Tract of Women. Curr Infect Dis Rep 2009; 10:505511.
  • 15
    Cohen M, Hoffman IF, Royce RA, Kazembe P, Dyer JR, Daly CC, Zimba D, Vernazza PL, Maida M, Fiscus SA, Eron Jr JJ: Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. AIDSCAP Malawi Research Group. Lancet 1997; 349:18681873.
  • 16
    McClelland R, Wang CC, Mandaliya K, Overbaugh J, Reiner MT, Panteleeff DD, Lavreys L, Ndinya-Achola J, Bwayo JJ, Kreiss JK: Treatment of cervicitis is associated with decreased cervical shedding of HIV-1. AIDS 2001; 15:105110.
  • 17
    Rotchford K, Strum AW, Wilkinson D: Effect of coinfection with STDs and of STD treatment on HIV shedding in genital-tract secretions: systematic review and data synthesis. Sex Transm Dis 2000; 27:243248.
  • 18
    Ding J, Rapista A, Teleshova N, Mosoyan G, Jarvis GA, Klotman ME, Chang TL: Neisseria gonorrhoeae enhances HIV-1 infection of primary resting CD4+ T cells through TLR2 activation. J Immunol 2010; 184:28142824.
  • 19
    Zhang J, Li G, Bafica A, Pantelic M, Zhang P, Broxmeyer H, Liu Y, Wetzler L, He JJ, Chen T: Neisseria gonorrhoeae enhances infection of dendritic cells by HIV type 1. J Immunol 2005; 174:79958002.
  • 20
    Fichorova R, Trifonova RT, Gilbert RO, Costello CE, Hayes GR, Lucas JJ, Singh BN: Trichomonas vaginalis lipophosphoglycan triggers a selective upregulation of cytokines by human female reproductive tract epithelial cells. Infect Immun 2008; 74:57735779.
  • 21
    Bastida-Corcuera F, Okumura CY, Colocoussi A, Johnson PJ: Trichomonas vaginalis lipophosphoglycan mutants have reduced adherence and cytotoxicity to human ectocervical cells. Eukaryot Cell 2005; 4:19511958.
  • 22
    Padian N, McCoy SI, Balkus JE, Wasserheit JN: Weighing the gold in the gold standard: challenges in HIV prevention research. AIDS 2010; 24:621635.
  • 23
    Grosskurth H, Mosha F, Todd J, Mwijarubi E, Klokke A, Senkoro K, Mayaud P, Changalucha J, Nicoll A, ka-Gina G: Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet 1995; 346:530536.
  • 24
    Orrorth K, Gavyole A, Todd J, Mosha F, Ross D, Mwijarubi E, Grosskurth H, Hayes RJ: Syndromic treatment of sexually transmitted diseases reduces the proportion of incident HIV infections attributable to these diseases in rural Tanzania. AIDS 2000; 14:14291437.
  • 25
    Wawer M, Sewankambo NK, Serwadda D, Quinn TC, Paxton LA, Kiwanuka N, Wabwire-Mangen F, Li C, Lutalo T, Nalugoda F, Gaydos CA, Moulton LH, Meehan MO, Ahmed S, Gray RH: Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomised community trial. Rakai Project Study Group. Lancet 1999; 353:525535.
  • 26
    Korenromp E, White RG, Orroth KK, Bakker R, Kamali A, Serwadda D, Gray RH, Grosskurth H, Habbema JDF, Hayes RJ: Determinants of the impact of sexually transmitted infection treatment on prevention of HIV infection: a synthesis of evidence from the Mwanza, Rakai, and Masaka intervention trials. J Infect Dis 2005; 191:S168S178.
  • 27
    White R, Orroth KK, Korenromp EL, Bakker R, Wambura M, Sewankambo NK, Gray RH, Kamali A, Whitworth JAG, Grosskurth H, Habbema JDF, Hayes RJ: Can population differences explain the contrasting results of the Mwanza, Rakai, and Masaka HIV/Sexually Transmitted Disease Intervention Trials? J Acquir Immune Def Syndr 2004; 37:15001513.
  • 28
    Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, Meehan MO, Lutalo T, Gray RH: Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342:921929.
  • 29
    Kamali A, Quigley M, Nakiyingi J, Kinsman J, Kengeya-Kayondo J, Gopal R, Ojwiya A, Hughes P, Carpenter LM, Whitworth J: Syndromic management of sexually-transmitted infections and behaviour change interventions on transmission of HIV-1 in rural Uganda: a community randomised trial. Lancet 2003; 361:645652.
  • 30
    Kaul R, Kimani J, Nagelkerke NJ, Fonck K, Ngugi EN, Keli F, MacDonald KS, Maclean IW, Bwayo JJ, Temmerman M, Ronald AR, Moses S, Kibera HIV Study Group: Monthly antibiotic chemoprophylaxis and incidence of sexually transmitted infections and HIV-1 infection in Kenyan sex workers: a randomized controlled trial. J Am Med Assoc 2004; 291:25552562.
  • 31
    Corey L, Wald A, Celum CL, Quinn TC: The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Def Syn 2004; 35:435445.
  • 32
    Wald A, Ashley-Morrow R: Serological testing for herpes simplex virus (HSV)-1 and HSV-2 infection. Clin Infect Dis 2002; 35:S173S182.
  • 33
    Freeman E, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ: Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006; 20:7383.
  • 34
    Abu-Raddad L, Magaret AS, Celum C, Wald A, Longini Jr IM, Self SG, Corey L: Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa. Sex Transm Dis 2008; 3:e2230.
  • 35
    Sangani P, Rutherford G, Wilkinson D: Population-based interventions for reducing sexually transmitted infections, including HIV infection. Cochrane Database Syst Rev 2004; 2:CD001220.
  • 36
    Tobian A, Quinn TC: Herpes simplex virus type 2 and syphilis infections with HIV: an evolving synergy in transmission and prevention. Curr Opin HIV AIDS 2009; 4:294299.
  • 37
    Glynn J, Biraro S, Weiss HA: Herpes simplex virus type 2: a key role in HIV incidence. AIDS 2009; 23:15951598.
  • 38
    Van de Perre P, Segondy M, Foulongne V, Ouedraogo A, Konate I, Huraux JM, Mayaud P, Nagot N: Herpes simplex virus and HIV-1: deciphering viral synergy. Lancet Infect Dis 2008; 8:490497.
  • 39
    Wald A, Zeh J, Selke S, Warren T, Ryncarz AJ, Ashley R, Krieger JN, Corey L: Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med 2000; 342:844850.
  • 40
    Johnson K, Sherman ME, Ssempiija V, Tobian AA, Zenilman JM, Duggan MA, Kigozi G, Serwadda D, Wawer MJ, Quinn TC, Rabkin CS, Gray RH: Foreskin inflammation is associated with HIV and herpes simplex virus type-2 infections in Rakai, Uganda. AIDS 2009; 23:18071815.
  • 41
    Tobian A, Ssempijja V, Kigozi G, Oliver AE, Serwadda D, Makumbi F, Nalugoda FK, Iga B, Reynolds SJ, Wawer MJ, Quinn TC, Gray RH: Incident HIV and herpes simplex virus type 2 infection among men in Rakai, Uganda. AIDS 2009; 23:15891594.
  • 42
    Wald A, Link K: Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis 2002; 185:4552.
  • 43
    Brown J, Wald A, Hubbard A, Rungruengthanakit K, Chipato T, Rugpao S, Mmiro F, Celentano DD, Salata RS, Morrison CS, Richardson BA, Padian NS: Incident and prevalent herpes simplex virus type 2 infection increases risk of HIV acquisition among women in Uganda and Zimbabwe. AIDS 2007; 21:15151523.
  • 44
    Brown E, Wald A, Hughes JP, Morrow RA, Krantz E, Mayer K, Buchbinder S, Koblin B, Celum C: High risk of human immunodeficiency virus in men who have sex with men with herpes simplex virus type 2 in the EXPLORE study. Am J Epidemiol 2006; 164:733741.
  • 45
    Celum C: The interaction between herpes simplex virus and human immunodeficiency virus. Herpes 2004; 11:36A45A.
  • 46
    Celum C, Levine R, Weaver M, Wald A: Genital herpes and human immunodeficiency virus: double trouble. Bull World Health Org 2004; 82:447453.
  • 47
    Watson-Jones D, Weiss HA, Rusizoka M, Changalucha J, Baisley K, Mugeye K, Tanton C, Ross D, Everett D, Clayton T, Balira R, Knight L, Hambleton I, Le Goff J, Belec L, Hayes R: HSV trial team; Steering and Data Monitoring Committees. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med 2008; 358:15601571.
  • 48
    Celum C, Wald A, Hughes J, Sanchez J, Reid S, Delany-Moretlwe S, Cowan F, Casapia M, Ortiz A, Fuchs J, Buchbinder S, Koblin B, Zwerski S, Rose S, Wang J, Corey L, HPTN 039 Protocol Team: Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 371:21092119.
  • 49
    Celum C, Wald A, Lingappa JR, Magaret AS, Wang RS, Mugo N, Mujugira A, Baeten JM, Mullins JI, Hughes JP, Bukusi EA, Cohen CR, Katabira E, Ronald A, Kiarie J, Farquhar C, Stewart GJ, Makhema J, Essex M, Were E, Fife KH, de Bruyn G, Gray GE, McIntyre JA, Manongi R, Kapiga S, Coetzee D, Allen S, Inambao M, Kayitenkore K, Karita E, Kanweka W, Delany S, Rees H, Vwalika B, Stevens W, Campbell MS, Thomas KK, Coombs RW, Morrow R, Whittington WL, McElrath MJ, Barnes L, Ridzon R, Corey L, Partners in Prevention HSV/HIV Transmission Study Team: Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med 2010; 362:427739.
  • 50
    Lingappa J, Kahle E, Mugo N, Mujugira A, Magaret A, Baeten J, Bukusi EA, Cohen CR, Katabira E, Ronald A, Kiarie J, Farquhar C, Stewart GJ, Makhema J, Essex M, Were E, Fife K, Debruyn G, Gray G, McIntyre J, Manongi R, Kapiga S, Coetzee D, Allen S, Inambao M, Kayitenkore K, Karita E, Kanweka W, Delany S, Rees H, Vwalika B, Coombs RW, Morrow R, Whittington W, Corey L, Wald A, Celum C, Partners HSV-2/HIV-1 Transmission Study Team: Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study. PLoS ONE 2009; 4:e5272.
  • 51
    Barnabas R, Wasserheit JN: Riddle of the Sphinx revisited: the role of STDs in HIV prevention. Sex Transm Dis 2009; 36:365367.
  • 52
    Vanpouille C, Lisco A, Margolis L: Acyclovir: a new use for an old drug. Curr Opin Infect Dis 2009; 22:583587.
  • 53
    Zhu J, Koelle DM, Cao J, Vazquez J, Huang ML, Hladik F, Wald A, Corey L: Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J Exp Med 2007; 204:595603.
  • 54
    Zhu J, Hladik F, Woodward A, Klock A, Peng T, Johnston C, Remington M, Magaret A, Koelle DM, Wald A, Corey L: Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat Med 2009; 15:886892.
  • 55
    Kaul R, Nagelkerke NJ, Kimani J, Ngugi E, Bwayo JJ, MacDonald KS, Rebbaprgada A, Fonck K, Temmerman M, Ronald AR, Moses S, Kibera HIV Study Group: Prevalent herpes simplex virus type 2 infection is associated with altered vaginal flora and an increased susceptability to multiple sexually transmitted infections. J Infect Dis 2007; 196:16921697.
  • 56
    Ward H, Rönn M: Contribution of sexually transmitted infections to the sexual transmission of HIV. Curr Opin HIV AIDS 2010; 5:305310.
  • 57
    Gray R, Wawer MJ: Reassessing the hypothesis on STI control for HIV prevention. Lancet 2008; 371:20642065.
  • 58
    Mayer K, Venkatesh KK: Antiretroviral Therapy for HIV Prevention: Current status and future prospects. Am J Pub Health 2010; 100:18671876.
  • 59
    van de Wijgert J, Morrison CS, Brown J, Kwok C, Van Der Pol B, Chipato T, Byamugisha JK, Padian N, Salata RA: Disentangling contributions of reproductive tract infections to HIV acquisition in African Women. Sex Transm Dis 2009; 36:357364.
  • 60
    Braunstein S, van de Wijgert JH, Nash D: HIV incidence in sub-Saharan Africa: a review of available data with implications for surveillance and prevention planning. AIDS Rev 2009; 3:140156.
  • 61
    Adimora A, Schoenbach VJ, Floris-Moore MA: Ending the epidemic of heterosexual HIV transmission among African Americans. Am J Prev Med 2009; 37:468471.
  • 62
    Mayer K, Bush T, Conley L, Henry K, Overton T, Richardson J, Wood K, Brooks JT: Clinical and behavioral characteristics of HIV-infected American patients in care at increased risk of transmission to others. Paper presented at: XVII International AIDS Conference; August 3–8, Mexico City, 2008.
  • 63
    Anderson D, Politch JA, Nadolski AM, Blaskewicz CD, Pudney J, Mayer KH: Targeting Trojan Horse leukocytes for HIV prevention. AIDS 2010; 24:163187.
  • 64
    Quayle A, Xu C, Mayer KH, Anderson DJ: T lymphocytes and macrophages, but not motile spermatozoa, are a significant source of human immunodeficiency virus in semen. J Infect Dis 1997; 176:960968.
  • 65
    Anderson B, Wang CC, Delong AK, Liu T, Kojic EM, Kurpewski J, Ingersoll J, Mayer K, Caliendo AM, Cu-Uvin S: Genital tract leukocytes and shedding of genital HIV type 1 RNA. Clin Infect Dis 2008; 47:12161221.
  • 66
    Anderson D, O’Brien TR, Politch JA, Martinez A, Seage 3rd GR, Padian N, Horsburgh Jr CR, Mayer KH: Effects of disease stage and zidovudine therapy on the detection of human immunodeficiency virus type 1 in semen. J Am Med Assoc 1992; 267:27692774.
  • 67
    Politch J, Mayer KH, Anderson DJ: Depletion of CD4+ T cells in semen during HIV infection and their restoration following antiretroviral therapy. J Acquir Immune Def Syn 2009; 50:283289.
  • 68
    Granich R, Crowley S, Vitoria M, Lo YR, Souteyrand Y, Dye C, Gilks C, Guerma T, De Cock KM, Williams B: Highly active antiretroviral treatment for the prevention of HIV transmission. J Int AIDS Soc 2010; 12:1.
  • 69
    Granich R, Gilks CF, Dye C, De Cock KM, Williams BG: Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373:4857.
  • 70
    Wolday D, Gebremariam Z, Mohammed Z, Dorigo-Zetsma W, Meles H, Messele T, Geyid A, Sanders E, Maayan S: The impact of syndromic treatment of sexually transmitted diseases on genital shedding of HIV-1. AIDS 2004; 18:781785.